welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
researchers
Eugene Gerner, PhD
Researcher Director
Gastrointestinal Cancer Program
Arizona Cancer Center
Tucson, Arizona, United States
CEO, Cancer Prevention Pharmaceuticals (CPP)
Cancer Prevention Pharmaceuticals (CPP) is a company in the late stages of developing drugs and drug combinations to treat people with risk factors for cancer. Some of these people have genetic risk factors, such as defects in the adenomatous poly posits coli tumor suppressor gene which cause the familial adenomatous polyposis (FAP) syndrome. Others have sporadic risk factors, such as prior colorectal cancer or neuroblastoma with amplified copies of the MYCN oncogene. CPP is also developing companion diagnostics for its drug therapies.
expertly curated content related to this topic
-
Celecoxib, DFMO combination improved adenoma burden in patients with familial adenomatous polyposisIn a randomized clinical chemoprevention...
-
Revealing the Power of the Rare Disease Community With State-of-the Art Collaborative, Trustworthy, Digital Educatio...The growth of online communities in ...
-
stephanie c. nnadi, phdDepartment of Biology...
-
Banner MD Anderson Cancer CenterAt Banner MD Anderson Cancer Center, col...
-
Gabriela MosleinGabriela Möslein is a surgeon and colop...
-
Monica M. Bertagnolli, MDDr. Bertagnolli is Professor at Harvard ...
-
Randall E. Brand, MDProfessor of Medicine Academic Director...